Search results for "Immune system"

showing 10 items of 2885 documents

Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma

2018

The advent of immune checkpoint (ICP) blockade has introduced an unprecedented paradigm shift in the treatment of cancer. Though very promising, there is still a substantial proportion of patients who do not respond or develop resistance to ICP blockade. In vitro and in vivo models are eagerly needed to identify mechanisms to maximize the immune potency of ICP blockade and overcome primary and acquired resistance to ICP blockade. Vγ9Vδ2 T cells isolated from the bone marrow (BM) from multiple myeloma (MM) are excellent tools to investigate the mechanisms of resistance to PD-1 blockade and to decipher the network of mutual interactions between PD-1 and the immune suppressive tumor microenvir…

0301 basic medicineCancer Researchmedicine.medical_treatmentMini Reviewlcsh:RC254-28203 medical and health sciences0302 clinical medicineImmune systemIn vivoMedicinetumor vaccinationVg9Vd2 T cells immune checkpoint blockade immunotherapy tumor vaccination multiple myelomaMultiple myelomaTumor microenvironmentVg9Vd2 T cellsbusiness.industryImmunotherapyimmune checkpoint blockadelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseVγ9Vδ2 T cellsImmune checkpointBlockademultiple myeloma030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchBone marrowimmunotherapybusinessFrontiers in Oncology
researchProduct

Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy

2020

Simple Summary The aim of this review is to detailed immunological effects of chemotherapies focusing on 2 main effects: immunogenic cell death and depletion of suppressive cells. It provides a strong rational for combination of chemotherapy and immunotherapy. Abstract Chemotherapy is initially used to kill proliferative cells. In the current area of emerging immunotherapy, chemotherapies have shown their ability to modulate the tumor micro environment and immune response. We focus here on two main effects: first, immunogenic cell death, defined as a form of regulated cell death (RCD) that is sufficient to activate an adaptive immune response in immunocompetent hosts; and second, the deplet…

0301 basic medicineCancer Researchmedicine.medical_treatmentReviewchemotherapylcsh:RC254-28203 medical and health sciences0302 clinical medicineImmune systemImmunityChemoimmunotherapyimmunogenic cell deathmedicinecancerChemotherapyimmunosuppressionbusiness.industryImmunosuppressionImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensAcquired immune system030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchImmunogenic cell deathimmunotherapybusinessCancers
researchProduct

Platelet-Derived GARP Induces Peripheral Regulatory T Cells—Potential Impact on T Cell Suppression in Patients with Melanoma-Associated Thrombocytosis

2020

Platelets have been recently described as an important component of the innate and adaptive immunity through their interaction with immune cells. However, information on the platelet&ndash

0301 basic medicineCancer Researchmedicine.medical_treatmentT cellanimal diseaseschemical and pharmacologic phenomenathrombocytosisBiologylcsh:RC254-282Article03 medical and health sciences0302 clinical medicineImmune systemGARPDownregulation and upregulationmedicinemelanomaPlateletIL-2 receptorFOXP3Immunotherapybiochemical phenomena metabolism and nutritionAcquired immune systemlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensTreg030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisplateletsCancer researchbacteriaCancers
researchProduct

Role of Hypoxia and the Adenosine System in Immune Evasion and Prognosis of Patients with Brain Metastases of Melanoma: A Multiplex Whole Slide Immun…

2020

Simple Summary The introduction of immune-checkpoint inhibitors improved the therapeutic landscape for patients with advanced malignant melanoma. However, many patients, including patients with melanoma brain metastases, do not derive benefit from immune-checkpoint blockade. Hence, biomarkers are needed to identify potential mechanisms of resistance and optimize patient selection. This study aimed to explore the role of hypoxia-mediated immunosuppression within the tumor microenvironment of patients with metastatic melanoma using multiplex immunofluorescence. We analyzed the prognostic relevance of the hypoxia surrogate marker GLUT-1, the adenosine-synthesizing ectoenzymes CD73/CD39, and th…

0301 basic medicineCancer Researchmultiplex immunohistochemistrymedicine.medical_treatmentimmune checkpoint inhibitorIpilimumablcsh:RC254-282Articlespatial statistics03 medical and health sciences0302 clinical medicineImmune systemmedicineCytotoxic T celltumor microenvironmentipilimumabradiotherapyTumor microenvironmentimmunosuppressionbusiness.industryhypoxiaMelanomaImmunosuppressionmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCTL*030104 developmental biologyOncologyadenosine030220 oncology & carcinogenesisCancer researchbusinessCD8medicine.drugCancers
researchProduct

Red wine extract disrupts Th17 lymphocyte differentiation in a colorectal cancer context

2020

International audience; Scope: Scope: It is well established that immune response and inflammation promote tumoral progression. Immune cells communicate through direct contact or through cytokine secretion, and it is the pro-inflammatory status that will tip the balance toward tumor progression or anti-tumor immunity. It is demonstrated here that a red wine extract (RWE) can decrease inflammation through its action on the inflammasome complex. This study determines whether an RWE could impact other key actors of inflammation, including T helper 17 (Th17) immune cells in particular. Methods and results: Methods and results: Using an RWE containing 4.16 g of polyphenols/liter of wine, it is s…

0301 basic medicineCancers polyphenolsred wine extractPlateforme de Transfert en Biologie du Cancer (PTBC) ChalminWineCancers Lipids[SHS]Humanities and Social Scienceslymphocyte T Red wine extractchemopreventionLymphocytesEmericMice Inbred BALB CDominiqueInterleukin-17Lymphocyte differentiationVin rougeCell DifferentiationFlavieSanté humaineLipidscolon cancerFemaleInterleukin 17medicine.symptomCancers LimagneColorectal NeoplasmsCancersCancers DelmasBiotechnologyOEnologieInflammationBiology03 medical and health sciencesLymphocytes Tumor-InfiltratingImmune systemCell Line TumorCancers CourtautmedicineAnimalsHumanslymphocytes Th17Cell ProliferationNutrition030109 nutrition & dieteticsFannyPlant ExtractsInterleukinsPolyphenolsHCT116 CellsAntineoplastic Agents PhytogenicXenograft Model Antitumor AssaysMice Inbred C57BL030104 developmental biologyTumor progressionSTAT proteinCancer researchTh17 CellsCytokine secretionVirginieInflammasome complex[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFood Science
researchProduct

Plastic and micro-evolutionary responses of a nematode to the host immune environment

2017

9 pages; International audience; Parasitic organisms have to cope with the defences deployed by their hosts and this can be achieved adopting immune evasion strategies or optimal life history traits according to the prevailing pattern of immune-mediated mortality. Parasites often encounter variable immune environments both within and between hosts, promoting the evolution of plastic strategies instead of fixed responses. Here, we explored the plasticity and micro-evolutionary responses of immunomodulatory mechanisms and life history traits to the immune environment provided by the host, using the parasitic nematode Heligmosomoides polygyrus. To test if the parasite responds plastically to t…

0301 basic medicineCandidate genePhenotypic plasticityFecesMice0302 clinical medicine[ SDV.EE.IEO ] Life Sciences [q-bio]/Ecology environment/Symbiosis[ SDV.IMM ] Life Sciences [q-bio]/ImmunologySerial PassageMice Inbred BALB CNematospiroides dubiusGeneral MedicineDNA HelminthInfectious DiseasesCytokines[SDV.IMM]Life Sciences [q-bio]/ImmunologyMicro-evolutionFemalemedicine.symptom[ SDV.MP.PAR ] Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyDNA ComplementaryImmunologyInflammationBiologyReal-Time Polymerase Chain ReactionLife history theoryImmunomodulation03 medical and health sciencesImmune systemmedicineAnimals[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyRNA MessengerParasite Egg CountSelectionGeneStrongylida InfectionsAnalysis of VarianceHost (biology)Life history traitsbiology.organism_classification030104 developmental biologyNematodeImmunologyLinear ModelsbacteriaParasitologyGene expressionHeligmosomoides polygyrusRNA Helminth[SDV.EE.IEO]Life Sciences [q-bio]/Ecology environment/Symbiosis030215 immunologyExperimental Parasitology
researchProduct

Innate Sensing through Mesenchymal TLR4/MyD88 Signals Promotes Spontaneous Intestinal Tumorigenesis

2019

Summary MyD88, an adaptor molecule downstream of innate pathways, plays a significant tumor-promoting role in sporadic intestinal carcinogenesis of the Apcmin/+ model, which carries a mutation in the Apc gene. Here, we show that deletion of MyD88 in intestinal mesenchymal cells (IMCs) significantly reduces tumorigenesis in this model. This phenotype is associated with decreased epithelial cell proliferation, altered inflammatory and tumorigenic immune cell infiltration, and modified gene expression similar to complete MyD88 knockout mice. Genetic deletion of TLR4, but not interleukin-1 receptor (IL-1R), in IMCs led to altered molecular profiles and reduction of intestinal tumors similar to …

0301 basic medicineCarcinogenesisBiologymedicine.disease_causeArticleGeneral Biochemistry Genetics and Molecular BiologyExtracellular matrixMice03 medical and health sciences0302 clinical medicinemedicinetumor microenvironmentAnimalsHumansReceptorinnate immunityTumor microenvironmentInnate immune systemMesenchymal stem cellCell biologyIntestinesToll-Like Receptor 4030104 developmental biologyMyeloid Differentiation Factor 88Knockout mouseTLR4Carcinogenesiscancer-associated fibroblasts030217 neurology & neurosurgerySignal Transduction
researchProduct

Mcl-1 targeting could be an intriguing perspective to cure cancer

2018

The Bcl-2 family, which plays important roles in controlling cancer development, is divided into antiapoptotic and proapoptotic members. The change in the balance between these members governs the life and death of the cells. Mcl-1 is an antiapoptotic member of this family and its distribution in normal and cancerous tissues strongly differs from that of Bcl-2. In human cancers, where upregulation of antiapoptotic proteins is common, Mcl-1 expression is regulated independent of Bcl-2 and its inhibition promotes senescence, a major barrier to tumorigenesis. Cancer chemotherapy determines various kinds of responses, such as senescence and autophagy; however, the ideal response to chemotherapy…

0301 basic medicineCarcinogenesisPhysiologyClinical BiochemistryApoptosisBiologymedicine.disease_causecancer care03 medical and health sciencesMcl-1 in cancer0302 clinical medicineBcl-2 familyimmune system diseasesCancer stem cellhemic and lymphatic diseasesNeoplasmsmedicinecancer-stem-cellHumansPost-translational regulationMolecular Targeted TherapyneoplasmsCellular SenescenceOncogeneBcl-2 familyAutophagyCancerCell Biologymedicine.diseaseMcl-1 isoformGene Expression Regulation Neoplastic030104 developmental biologyUSP9XProto-Oncogene Proteins c-bcl-2030220 oncology & carcinogenesisCancer researchtargeting Mcl-1Myeloid Cell Leukemia Sequence 1 ProteinCarcinogenesisProtein Processing Post-Translational
researchProduct

WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer

2019

Triple-negative breast cancers (TNBCs) are characterized by a poor prognosis and lack of targeted treatments, and thus, new therapeutic strategies are urgently needed. Inhibitors against programmed death-1 (PD-1)/PD-1 ligand (PD-L1) have shown significant efficacy in various solid cancers, but their activity against TNBCs remains limited. Here, we report that human TNBCs molecularly stratified for high levels of PD-L1 (PD-L1High) showed significantly enriched expression of immune and cancer stemness pathways compared with those with low PD-L1 expression (PD-L1Low). In addition, the PD-L1High cases were significantly associated with a high stemness score (SSHigh) signature. TNBC cell lines g…

0301 basic medicineCell biologyCancer ResearchTriple Negative Breast NeoplasmImmunologyDown-RegulationTriple Negative Breast NeoplasmsArticleB7-H1 Antigen03 medical and health sciences0302 clinical medicineImmune systemStem CellCell Line TumorBiomarkers TumorGeneticsmedicineAnimalsHumansWnt Signaling PathwayMolecular BiologyTriple-negative breast cancerMice Inbred BALB CbiologyAnimalStem CellsCD44Wnt signaling pathwayCancerAldehyde Dehydrogenasemedicine.diseaseHyaluronan ReceptorUp-RegulationALDH1A1Hyaluronan Receptors030104 developmental biology030220 oncology & carcinogenesisbiology.proteinCancer researchFemaleStem cellB7-H1 AntigenHumanOncogene
researchProduct

Tissue factor at the crossroad of coagulation and cell signaling

2018

The tissue factor (TF) pathway plays a central role in hemostasis and thrombo-inflammatory diseases. Although structure-function relationships of the TF initiation complex are elucidated, new facets of the dynamic regulation of TF?s activities on cells continue to emerge. Cellular pathways that render TF non-coagulant participate in signaling of distinct TF complexes with associated proteases through the protease-activated receptor (PAR) family of G-protein coupled receptors. Additional coreceptors, including the endothelial protein C receptor (EPCR) and integrins, confer signaling specificity by directing subcellular localization and trafficking. We here review how TF is switchedbetween it…

0301 basic medicineCell signalingProteasesCIENCIAS MÉDICAS Y DE LA SALUDIntegrinInmunologíaFactor VIIaThromboplastin03 medical and health sciencesTissue factorPROTEINASE- ACTIVATED RECEPTORSNeoplasmsmedicineAnimalsHumansReceptor PAR-2Myeloid CellsHEMOSTASISProtease-activated receptorENDOTHELIAL PROTEIN C RECEPTORBlood CoagulationInflammationEndothelial protein C receptorInnate immune systembiologyChemistryEndothelial CellsThrombosisInflammasomeHematologyCell biologyTHROMBOSISMedicina Básica030104 developmental biologyFactor Xabiology.proteinPROTEIN DISULFIDE-ISOMERASESSignal Transductionmedicine.drugJournal of Thrombosis and Haemostasis
researchProduct